How to Get $25 Wegovy: The Savings Card, Eligibility Rules, and What to Do If You Do Not Qualify

Key Takeaways (highlighted box)

• The Novo Nordisk Wegovy Savings Card can lower eligible commercial-insurance copays to as little as $25 per 28-day supply, with a benefit cap around $225 per fill.
• Eligibility requires commercial insurance that covers Wegovy, a U.S. address, and no enrollment in any government plan (Medicare, Medicaid, TRICARE, VA).
• Patients without commercial coverage of Wegovy can still pay $499 to $650 cash through NovoCare Pharmacy direct-ship, but that is not the $25 price.
• If your insurance does not cover Wegovy, the savings card will not magically reduce your cost; it works only as a copay reducer on top of an existing covered claim.
• Compounded semaglutide is the most common alternative for patients who cannot get the $25 price, with cash pricing of $179 to $279 per month.

Direct answer (40-60 words)

You get $25 Wegovy by enrolling in the Novo Nordisk Wegovy Savings Card and using it at the pharmacy alongside commercial insurance that already covers Wegovy. The card reduces eligible copays to as little as $25 per 28-day supply. Medicare, Medicaid, TRICARE, and VA patients are not eligible due to federal anti-kickback rules.

Table of contents

1. The 30-second answer
2. What the Wegovy Savings Card actually does
3. Eligibility checklist (read this first)
4. Step-by-step: getting the $25 price at the pharmacy
5. The fine print: caps, fill limits, and exclusions
6. What to do if your insurance does not cover Wegovy
7. The NovoCare direct-ship option (not $25, but cheaper than retail cash)
8. Wegovy vs Ozempic for the savings card
9. The compounded semaglutide alternative
10. FAQ
11. Sources
12. Footer disclaimers

What the Wegovy Savings Card actually does

The Wegovy Savings Card is a manufacturer copay assistance program from Novo Nordisk. Three things to understand about how it works:

1. It is a copay reducer, not a coupon. The card does not lower the list price of Wegovy. It pays down your existing insurance copay, up to a per-fill benefit cap. If your insurance copay is already $0, the card adds nothing. If your insurance does not cover Wegovy at all, the card cannot help because there is no copay to reduce.

2. It works alongside commercial insurance only. Federal anti-kickback rules prohibit drug manufacturers from giving copay assistance to patients on government-funded insurance (Medicare, Medicaid, TRICARE, VA, IHS). Anyone enrolled in those programs is excluded.

3. It has a per-fill benefit cap. As of 2026, the card pays up to roughly $225 toward your copay per 28-day fill. If your copay is $300, you would pay $75 after the card. If your copay is $200, you would pay $25 after the card. The "$25 Wegovy" price applies when the copay reduction lands on the $25 floor.

The card is free to use. Novo Nordisk recovers value through increased prescription volume.

Eligibility checklist (read this first)

Before you spend time enrolling, confirm all five items below. Missing any one means the $25 price is not available to you.

• Commercial insurance. Employer plan, marketplace ACA plan, individual private plan. Not Medicare, Medicaid, TRICARE, VA, IHS, or any state-funded plan.
• Insurance covers Wegovy. Most commercial plans require prior authorization and BMI documentation (BMI 30, or BMI 27 with a weight-related comorbidity). Check your formulary.
• U.S. resident. Must have a U.S. mailing address. Card is not valid in territories that follow Medicare rules (including most of Puerto Rico for Part D enrollees).
• 18 years or older (Wegovy is approved for adolescent obesity at age 12-plus, but the savings card is currently restricted to adults; some pediatric programs exist separately).
• Active Wegovy prescription from a licensed U.S. provider.

If all five are true, you are likely eligible. If any are false, jump to the "What to do if your insurance does not cover Wegovy" section below.

Step-by-step: getting the $25 price at the pharmacy

Step 1: Confirm Wegovy is on your insurance formulary with PA approval. Log into your insurance member portal. Search "semaglutide" or "Wegovy" in the formulary tool. Note the tier and PA requirements. If PA is required and not yet submitted, your provider's office handles this. Approval takes 3 to 14 business days.

Step 2: Enroll in the savings card on the Wegovy website. Visit the official Wegovy website and click the savings card link. Enter your name, email, ZIP, and confirm eligibility. The system generates a digital card with a Group Number, BIN, and PCN. Print or save to your phone.

Step 3: Bring both cards to the pharmacy. Bring your insurance card and your Wegovy Savings Card to the pharmacy when you fill the prescription. Tell the pharmacist you have a manufacturer copay card.

Step 4: The pharmacist runs insurance first, then the savings card. The pharmacist processes your insurance claim normally, which produces a copay amount. They then process the savings card as a secondary claim, which reduces your out-of-pocket cost by the eligible benefit amount.

Step 5: Pay the reduced amount. The receipt should show the original copay, the savings card reduction, and your final payment. The lowest possible final payment under the card terms is $25. If your printed receipt shows higher than $25, ask the pharmacist whether the card was applied correctly.

The fine print: caps, fill limits, and exclusions

Per-fill benefit cap. Approximately $225 per 28-day supply. If your copay is below $225 plus $25 = $250, you can hit the $25 floor. If your copay is higher, you will pay the difference between your copay and the $225 reduction.

Total fill limit. The Wegovy Savings Card historically has a 12 to 13 fill limit per year, with a lifetime max of 24 fills under earlier card versions. Novo Nordisk has updated terms periodically; the current card terms are printed on the digital card you enroll for.

Annual benefit cap. The card has an annual maximum benefit of around $1,800 (cumulative across fills). Once you hit it, the card stops reducing your copay until the calendar resets.

Exclusions:

• Anyone on Medicare, Medicaid, TRICARE, VA, IHS, or any government-funded plan.
• Patients in states that prohibit manufacturer copay coupons in certain plan types (a small but growing list; check your state).
• Compounded semaglutide does not count; the card applies only to brand-name Wegovy.
• Off-label use does not qualify if the prescription does not match Wegovy's FDA-approved indication.

What to do if your insurance does not cover Wegovy

The most common dead end: you have commercial insurance, but Wegovy is not covered, or PA was denied. The savings card cannot rescue this scenario. Five practical paths forward:

1. Appeal the PA denial. About half of Wegovy denials are overturned on appeal when the provider adds BMI documentation, comorbidity records (hypertension, sleep apnea, dyslipidemia), and evidence of failed alternatives.

2. Request a formulary exception. If Wegovy is not on the formulary at all, your provider can request an exception. Approval is harder than PA approval but possible.

3. Use NovoCare Pharmacy direct-ship. Novo Nordisk launched a direct-to-patient cash program through NovoCare Pharmacy in 2025. Cash price for Wegovy through NovoCare is $499 per month for self-pay patients without insurance coverage of Wegovy. This is not the $25 price, but it is roughly half of the retail cash price ($1,350+).

4. Switch employers or open enrollment. About 38% of large employers covered anti-obesity medications in 2024 per Mercer survey data; coverage is expanding. Marketplace silver plans on Healthcare.gov have varying coverage; some cover Wegovy with PA, others exclude it entirely. Open enrollment is the time to compare.

5. Compounded semaglutide. The most common alternative for patients without coverage. Compounded semaglutide is the same active ingredient prepared by a state-licensed compounding pharmacy in response to an individual prescription. Cash pricing of $179 to $279 per month is the lowest legitimate option for many patients.

The NovoCare direct-ship option (not $25, but cheaper than retail cash)

NovoCare Pharmacy is Novo Nordisk's direct-to-patient cash program for Wegovy patients without coverage. Launched in 2025, it operates through Hims, NovoCare's own platform, and a few other partners.

Pricing (Q1 2026):

• $499 per month for the 1.7 mg dose
• $499 per month for the 2.4 mg maintenance dose
• 0.25 mg, 0.5 mg, 1 mg starter doses are around $499 to $650 depending on partner

Eligibility:

• Cash-pay patients (no insurance, or insurance does not cover Wegovy)
• Commercial-insured patients can also use it instead of running through insurance

What it does NOT do:

• It does not lower the price to $25.
• It does not stack with the savings card.
• It does not count toward your insurance deductible.

For a patient with no Wegovy coverage who wants brand-name semaglutide, NovoCare at $499 is currently the lowest brand-name price. For a patient willing to consider compounded, $179 to $279 per month is lower still.

For more, see /articles/cost-and-insurance/wegovy-cost/.

Wegovy vs Ozempic for the savings card

Both have separate savings cards through Novo Nordisk. Quick comparison:

A patient with commercial insurance who has both type 2 diabetes and obesity could in theory be prescribed Ozempic for diabetes and use the Ozempic card. Switching the prescription from Wegovy to Ozempic to save money requires a clinical justification and is a provider conversation.

The compounded semaglutide alternative

For patients who cannot access the $25 Wegovy price (Medicare patients, those with no commercial coverage, those with denied PA), compounded semaglutide is the most common practical alternative.

Pricing for compounded semaglutide:

• FormBlends compounded semaglutide: $179 to $279 per month
• Other compounding-pharmacy telehealth: $199 to $499 per month
• Local 503A compounding pharmacy: $150 to $350 per month

Important context:

• Compounded semaglutide is not FDA-approved.
• It is not interchangeable with brand-name Wegovy.
• It is drawn from a vial with a U-100 insulin syringe.
• It bypasses insurance, so there is no PA paperwork.

For the broader trade-off discussion, see /articles/glp1-hub/compounded-semaglutide-for-weight-loss-complete-guide-2026.

FAQ

How do you get $25 Wegovy? Enroll in the Novo Nordisk Wegovy Savings Card on the Wegovy website and use it alongside commercial insurance that already covers Wegovy with prior authorization approved. The card reduces eligible copays to as low as $25 per 28-day fill, capped at about $225 per fill of benefit.

Who qualifies for the $25 Wegovy savings card? Adults 18-plus with commercial insurance that covers Wegovy, a U.S. mailing address, and an active Wegovy prescription. Patients on Medicare, Medicaid, TRICARE, VA, or any government-funded plan are not eligible.

Can Medicare patients get $25 Wegovy? No. Federal anti-kickback rules prohibit manufacturer copay cards from being used by Medicare beneficiaries. The same rule applies to Medicaid, TRICARE, VA, and IHS. Medicare patients without coverage typically pay through the NovoCare cash program at $499 per month or use compounded alternatives.

Will the Wegovy savings card work if my insurance does not cover Wegovy? No. The card reduces an existing insurance copay; it does not replace coverage. If your plan denies Wegovy entirely, the card cannot help. Options in that case include appealing the denial, NovoCare cash at $499 per month, or compounded semaglutide.

How do I enroll in the Wegovy savings card? Visit the Wegovy website, click the savings card link, and enter your information. The system generates a digital card with BIN, PCN, and Group Number that the pharmacist needs. You can print or save to your phone.

How much will I save with the Wegovy savings card? Up to about $225 per fill, capped at roughly $1,800 per year. If your copay is $250, you would pay $25 after the card. If your copay is $400, you would pay $175 after the card. The maximum savings effect lands on the $25 floor.

Does the Wegovy savings card work for compounded semaglutide? No. The card applies only to brand-name Wegovy. Compounded semaglutide has its own separate cash pricing through compounding pharmacies, typically $179 to $279 per month with no manufacturer card needed.

How many times can I use the Wegovy savings card? Roughly 12 to 13 fills per year, with annual benefit capped around $1,800. Card terms have changed periodically; check the digital card you enroll for to see current limits.

Is the Wegovy savings card a coupon I can find online? It is a manufacturer-issued copay card, not a generic coupon. Enroll directly through the official Wegovy website. Third-party "Wegovy coupon" sites may show GoodRx prices, which are a separate cash discount, not the $25 price.

Can I use the Wegovy savings card and GoodRx together? No. They are alternatives. If your insurance copay after the savings card is higher than the GoodRx price, you can choose to use GoodRx and skip the card. If the savings card brings you to $25, that beats GoodRx every time.

Is the $25 Wegovy price guaranteed? No. It is the lowest possible price under card terms, and it depends on your specific insurance copay. About 60% of card users in 2024 reported a final price under $50 per fill per Novo Nordisk public statements; not all reach $25.

What if my pharmacist says the savings card does not work? Sometimes pharmacy systems take a couple of tries. Ask the pharmacist to manually enter the BIN, PCN, and Group Number from the card. If it still does not run, call the savings card support number on the digital card; they can troubleshoot in real time.

Sources

1. Novo Nordisk. Wegovy (semaglutide injection 2.4 mg) Savings Card Terms and Conditions, 2026.
2. Novo Nordisk. Wegovy Prescribing Information, revised 2024.
3. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
4. Novo Nordisk. NovoCare Pharmacy direct-to-patient program announcement, 2025.
5. Office of Inspector General, U.S. Department of Health and Human Services. Anti-kickback statute and manufacturer copay assistance, advisory opinions 2014 to 2024.
6. Mercer National Survey of Employer-Sponsored Health Plans. Coverage trends for anti-obesity medications, 2024.
7. American Diabetes Association. Standards of Care in Diabetes 2025. Diabetes Care. 2025;48(Suppl 1).
8. Centers for Medicare and Medicaid Services. Medicare Part D drug exclusions, 2026.
9. Kaiser Family Foundation. State Medicaid coverage of obesity medications: a 50-state survey, 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. NovoCare is a service of Novo Nordisk. GoodRx is a trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.